World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
97
Citations
33452
World Ranking
9312
National Ranking
516

Overview

Klemens Budde is affiliated with Charité - University Medicine Berlin in Germany. Their research primarily spans the field of Medicine, with a significant focus on Transplantation, Surgery, Infectious Diseases, Public Health, Environmental and Occupational Health, and Nephrology.

The main topics of their work include:

  • Renal Transplantation Outcomes and Treatments
  • Organ Transplantation Techniques and Outcomes
  • Organ Donation and Transplantation
  • Renal Diseases and Glomerulopathies
  • Renal and Vascular Pathologies
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research

Frequent co-authors collaborating with Klemens Budde are:

  • Fabian Halleck
  • Bilgin Osmanodja
  • Eva Schrezenmeier
  • Mira Choi
  • Marcel G. Naik

They have published extensively in prominent journals, with frequent venues including:

  • Transplant International
  • Nephrology Dialysis Transplantation
  • Journal of Clinical Medicine
  • American Journal of Transplantation
  • Transplantation

Recent papers authored or co-authored by Klemens Budde include:

  • Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations, 2021, Pediatric Neurology
  • Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients, 2021, Science Immunology
  • Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients, 2021, Journal of Clinical Investigation
  • After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy, 2020, Kidney International
  • Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy, 2022, Kidney International

In addition to journal articles, Klemens Budde has contributed to book publications, including a work published by Springer Nature titled Klinische Entscheidungsfindung mit Künstlicher Intelligenz in 2023.

Best Publications

  • Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

    John J Bissler;J Christopher Kingswood;Elżbieta Radzikowska;Bernard A Zonnenberg

  • Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.

    Duska Dragun;Dominik N. Müller;Jan Hinrich Bräsen;Lutz Fritsche

  • Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus.

    F. Vincenti;S. Friman;E. Scheuermann;L. Rostaing

  • Everolimus in patients with autosomal dominant polycystic kidney disease.

    Gerd Walz;Klemens Budde;Marwan Mannaa;Jens Nürnberger

  • Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy : Second Consensus Report

    Mercè Brunet;Teun Van Gelder;Anders Åsberg;Vincent Haufroid;Vincent Haufroid

  • Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.

    Klemens Budde;Thomas Becker;Wolfgang Arns;Claudia Sommerer

  • Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.

    Nils Lachmann;Paul I. Terasaki;Klemens Budde;Lutz Liefeldt

  • CC chemokine receptor 5 and renal-transplant survival

    Michael Fischereder;Bruno Luckow;Berthold Hocher;Rudolf P Wüthrich

  • Biomarkers in acute kidney injury – pathophysiological basis and clinical performance

    E. V. Schrezenmeier;E. V. Schrezenmeier;J. Barasch;K. Budde;T. Westhoff

  • First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients

    Klemens Budde;Robert L. Schmouder;Reinhard Brunkhorst;Bjorn Nashan

  • Meta-analysis identifies multiple loci associated with kidney function–related traits in east Asian populations

    Y. Okada;X. Sim;X. Sim;M. J. Go;J. Y. Wu;J. Y. Wu

  • Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial

    Teun van Gelder;Helio Tedesco Silva;Johan W. de Fijter;Klemens Budde

  • Neutrophil gelatinase‐associated lipocalin: pathophysiology and clinical applications

    Eugenia Singer;Lajos Markó;Neal Paragas;Jonathan Barasch

  • PREDICTORS OF SUCCESS IN CONVERSION FROM CALCINEURIN INHIBITOR TO SIROLIMUS IN CHRONIC ALLOGRAFT DYSFUNCTION

    F Diekmann;K Budde;F Oppenheimer;L Fritsche

  • Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study.

    Klemens Budde;John Curtis;Gregory Knoll;Lawrence Chan

  • Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.

    Lionel Rostaing;Diego Cantarovich;Georges Mourad;Klemens Budde

  • Interleukin 6 is an autocrine growth factor for mesangial cells.

    Christian Ruef;Klemens Budde;Jill Lacy;Wolfgang Northemann

  • Three‐Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients

    Štefan Vítko;Raimund Margreiter;Willem Weimar;Jacques Dantal

  • Donor‐Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney Transplantation

    L. Liefeldt;S. Brakemeier;P. Glander;J. Waiser

  • Diets and enteral supplements for improving outcomes in chronic kidney disease

    Kamyar Kalantar-Zadeh;Noël J. Cano;Klemens Budde;Charles Chazot

Frequent Co-Authors

Petra Reinke
Petra Reinke Berlin-Brandenburger Centrum für Regenerative Therapien
Martin Zeier
Martin Zeier University Hospital Heidelberg
Lionel Rostaing
Lionel Rostaing Grenoble Alpes University
Dirk Kuypers
Dirk Kuypers KU Leuven
Rolf A.K. Stahl
Rolf A.K. Stahl Universität Hamburg
Teun van Gelder
Teun van Gelder Leiden University Medical Center
Allison Tong
Allison Tong University of Sydney
Jonathan C. Craig
Jonathan C. Craig Flinders University
Kai-Uwe Eckardt
Kai-Uwe Eckardt Charité - University Medicine Berlin
Josep M. Grinyó
Josep M. Grinyó University of Barcelona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers beyond the traditional MD path, there are numerous flexible and affordable online degree options to consider. These programs allow students to gain specialized knowledge and advance their careers while balancing other commitments.

One popular route is health administration. Many students look for affordable online mha programs to prepare for leadership roles in hospitals, clinics, and health systems. These programs focus on management, policy, and healthcare operations.

Advanced nursing professionals may aim to enroll in cheap online dnp programs. A Doctor of Nursing Practice (DNP) helps nurses move into top-tier clinical or administrative roles and meets growing healthcare needs.

For those intrigued by pharmaceuticals, an online pharmacy degree can open doors to work as a licensed pharmacist or in pharmaceutical research. This option is ideal for students seeking both clinical and business expertise.

Finally, the demand for data-driven professionals is increasing. Earning an online mhi (Master’s in Health Information) equips graduates for roles in data analysis, informatics, and health information technology.

Best Scientists Citing Klemens Budde

Trending Scientists

Recently Published Articles